News for Arbutus Biopharma Corporation (ABUS)

Arbutus Biopharma (ABUS) recorded a revenue increase of 15% year-over-year. Analyst consensus indicates an "Outperform" rating with a potential upside o

Imdusiran combination therapy has functionally cured 8 patients with chronic hepatitis B (cHBV) to date, including 2 patients who received no interferon AB-101

**media[617429]**

Data highlighted in late-breaker poster presentation shows that imdusiran achieves functional cure in chronic hepatitis B (cHBV) patients when combined with VTP

[url="]Alnylam Pharmaceuticals, Inc.[/url] (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the fir

Arbutus Biopharma (ABUS) to present five abstracts at EASL Congress 2025 in Amsterdam. Key findings include the efficacy of Imdusiran and AB-101 in trea

**media[602521]**

Here is how Arbutus Biopharma (ABUS) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.

Arbutus Biopharma (NASDAQ:ABUS) stock gains as the company announces a restructuring drive with a 57% workforce reduction. Read more here.

Arbutus (ABUS) delivered earnings and revenue surprises of 12.50% and 17.46%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Claim construction hearing for Pfizer/BioNTech mRNA-LNP vaccine litigation occurred in December 2024; outcome pending

Strategic transformation ongoing, positioning the Company as a focused leader in immunology and inflammatory diseasesHighly differentiated, potentially curative

BASEL, Switzerland and VANCOUVER, B.C. and WARMINSTER, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Genevant Sciences, a leading nucleic acid delivery company with

**media[555746]**

**media[555742]**

WARMINSTER, Pa., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation ( ABUS) (”œArbutus” or the ”œCompany”), a clinical-stage biopharmaceut

Transaction Overview On February 20, 2025, Whitefort Capital Management, LP (Trades, Portfolio) executed a strategic stock transaction involving Arbutus Biophar

We recently published a list of 10 Best Nasdaq Stocks Under $5 to Buy. In this article, we are going to take a look at where Arbutus Biopharma Corp.

The Nasdaq is one of the top three most-followed stock market indices in the United States, comprising over 2,500 stocks.